Joseph Douglas Lyon's Transactions in Corcept Therapeutics Inc.

Joseph Douglas Lyon, the Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported several transactions involving the company's common stock and stock options. On August 1, 2025, Lyon exercised stock options to acquire 5,823 shares of common stock at an exercise price of $13.56 per share. On the same day, he sold 5,823 shares of common stock at a weighted average price of $67.5129 per share, with the actual sale prices ranging from $67.24 to $67.945 per share. The sale was made pursuant to a 10b5-1 plan adopted on August 30, 2024. Following these transactions, Lyon owns 31,571 shares of common stock, including unvested restricted stock awards. The transactions were reported in a Form 4 filing with the SEC.